Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Consensus Recommendation of "Buy" from Analysts

Key Points

• Arcturus Therapeutics Holdings Inc. has received a consensus recommendation of "Buy" from eight analysts, with an average 1-year price target of $50.57.
• Institutional investors own 94.54% of Arcturus Therapeutics stock, with notable increases in stakes from companies like Deutsche Bank and Two Sigma Investments in the fourth quarter.
• In the most recent quarterly earnings report, Arcturus Therapeutics beat analysts' expectations, reporting $28.3 million in revenue and earnings of ($0.34) per share.

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) has been given an average rating of "Buy" by the eight ratings firms that are covering the stock, MarketBeat.com reports. Eight equities research analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $50.5714.

Several brokerages recently commented on ARCT. Leerink Partners decreased their price target on Arcturus Therapeutics from $63.00 to $54.00 and set an "outperform" rating on the stock in a research note on Friday, August 22nd. Citigroup reaffirmed a "buy" rating and issued a $49.00 price target (up previously from $47.00) on shares of Arcturus Therapeutics in a research note on Tuesday, August 12th. Wells Fargo & Company decreased their price target on Arcturus Therapeutics from $45.00 to $42.00 and set an "overweight" rating on the stock in a research note on Tuesday, August 12th. Scotiabank reiterated an "outperform" rating on shares of Arcturus Therapeutics in a research report on Wednesday, July 2nd. Finally, Wall Street Zen upgraded Arcturus Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, August 9th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ARCT. Ameriprise Financial Inc. grew its stake in Arcturus Therapeutics by 5.0% in the fourth quarter. Ameriprise Financial Inc. now owns 18,613 shares of the biotechnology company's stock valued at $316,000 after acquiring an additional 883 shares during the period. Deutsche Bank AG raised its holdings in Arcturus Therapeutics by 42.7% during the fourth quarter. Deutsche Bank AG now owns 24,768 shares of the biotechnology company's stock worth $420,000 after acquiring an additional 7,417 shares in the last quarter. Two Sigma Investments LP raised its holdings in Arcturus Therapeutics by 60.9% during the fourth quarter. Two Sigma Investments LP now owns 27,560 shares of the biotechnology company's stock worth $468,000 after acquiring an additional 10,430 shares in the last quarter. GAMMA Investing LLC raised its holdings in Arcturus Therapeutics by 3,482.9% during the first quarter. GAMMA Investing LLC now owns 5,231 shares of the biotechnology company's stock worth $550,000 after acquiring an additional 5,085 shares in the last quarter. Finally, Green Alpha Advisors LLC bought a new stake in Arcturus Therapeutics during the first quarter worth about $288,000. 94.54% of the stock is owned by institutional investors and hedge funds.

Arcturus Therapeutics Trading Down 0.7%

ARCT opened at $20.31 on Friday. The stock has a market cap of $551.62 million, a PE ratio of -9.11 and a beta of 2.39. Arcturus Therapeutics has a 1 year low of $8.04 and a 1 year high of $25.88. The stock's 50 day simple moving average is $16.45 and its 200-day simple moving average is $13.66.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last released its quarterly earnings data on Monday, August 11th. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.11) by $0.77. The business had revenue of $28.30 million for the quarter, compared to analysts' expectations of $17.64 million. Arcturus Therapeutics had a negative return on equity of 24.87% and a negative net margin of 49.26%. Equities analysts forecast that Arcturus Therapeutics will post -2.22 earnings per share for the current fiscal year.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.